Peer Review reports
From: The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
| Original Submission | ||
|---|---|---|
| 4 Dec 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 3 Aug 2023 | Reviewed | Reviewer Report - Alessandro Comandone |
| 27 Dec 2023 | Reviewed | Reviewer Report |
| 7 Jan 2024 | Author responded | Author comments - Xiaodong Tang |
| Resubmission - Version 3 | ||
| 7 Jan 2024 | Submitted | Manuscript version 3 |
| 24 Jan 2024 | Reviewed | Reviewer Report |
| 24 Jan 2024 | Reviewed | Reviewer Report - Alessandro Comandone |
| Resubmission - Version 4 | ||
| Submitted | Manuscript version 4 | |
| Publishing | ||
| 25 Jan 2024 | Editorially accepted | |
| 3 Feb 2024 | Article published | 10.1186/s12885-024-11921-7 |
You can find further information about peer review here.